Parathyroid hormone (PTH) is a well known skeletal mediator and is effective for building bone in situations of metabolic bone disease and localized osseous defects. Despite its clinical efficacy, its mechanisms of action are complex and have eluded bone biologists for decades. The anabolic actions of PTH are not simple activation of cells that form bone, but likely require accessory cells in an intricate temporal and spatial organization. Preliminary data from the project laboratory strongly support the ability of PTH to stimulate osteoblastic cell proliferation, but in an indirect manner through another cell type in the bone marrow microenvironment. Data is emerging of PTH actions to expand cells of the hematopoietic compartment in the bone marrow which may function in the impact of PTH in bone. The overall hypothesis is that PTH is anabolic in bone via its ability to increase osteoblast proliferation indirectly through modulation of cell/s of the hematopoietic lineage.
Three specific aims will elucidate the cellular targets of PTH action in its impact on hematopoietic cells and also link the angiogenic potential of hematopoietic cells with the osteoblastic phenotype in the anabolic actions of PTH in bone.
The first aim will identify and verify the hematopoietic cell/s that expand in response to PTH.
The second aim will elucidate the mechanistic aspects of the increase in hematopoietic cell numbers in response to PTH as they depend on proliferative or anti-apoptotic cell signaling events.
The third aim will determine if the increase in hematopoietic cell populations translates into increased osteoblast proliferation leading to bone formation and/or increased vascular support in bone in vivo. These studies will utilize novel animal models, solid cell signaling biochemical assays, and cell sorting strategies to address these aims. These studies will better clarify the cellular targets of PTH action in bone and extend our existing knowledge of key cellular regulators in bone to include cells of the hematopoietic lineage in the bone marrow microenvironment. The compelling impact of this work is in the application of PTH toward tissue regeneration such as in states of osseous defects due to development, trauma, and inflammatory diseases. It is likely that information garnered from these models will also be important for clarifying the mechanisms of PTH therapeutic action in the treatment of metabolic bone disease such as osteoporosis and in states of dysregulated PTH or PTHrP such as hyperparathyroidism and skeletal metastasis.

Public Health Relevance

Parathyroid hormone (PTH) is a normal protein made by the body, and has also been developed as a drug for the treatment of bone disorders. The mechanisms of how PTH works are complex and have eluded scientists for many years. This project will identify the cells that are targets for PTH action in the bone marrow and elucidate the pathways of its action to build bone. Information garnered from these studies will be important for optimizing treatment of metabolic bone diseases such as osteoporosis, hyperparathyroidism and skeletal metastasis, and in designing strategies to regenerate bone in localized skeletal defects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK053904-13
Application #
8136074
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Malozowski, Saul N
Project Start
1998-08-01
Project End
2013-06-30
Budget Start
2011-09-01
Budget End
2013-06-30
Support Year
13
Fiscal Year
2011
Total Cost
$317,814
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Dentistry
Type
Schools of Dentistry
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Koh, A J; Sinder, B P; Entezami, P et al. (2017) The skeletal impact of the chemotherapeutic agent etoposide. Osteoporos Int 28:2321-2333
Michalski, Megan N; McCauley, Laurie K (2017) Macrophages and skeletal health. Pharmacol Ther 174:43-54
Sinder, Benjamin P; Zweifler, Laura; Koh, Amy J et al. (2017) Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis. J Bone Miner Res 32:2116-2127
Dang, Ming; Koh, Amy J; Jin, Xiaobing et al. (2017) Local pulsatile PTH delivery regenerates bone defects via enhanced bone remodeling in a cell-free scaffold. Biomaterials 114:1-9
Michalski, Megan N; Koh, Amy J; Weidner, Savannah et al. (2016) Modulation of Osteoblastic Cell Efferocytosis by Bone Marrow Macrophages. J Cell Biochem 117:2697-2706
Wang, Chin-Wei Jeff; McCauley, Laurie K (2016) Osteoporosis and Periodontitis. Curr Osteoporos Rep 14:284-291
Wang, L; Tran, A B; Nociti Jr, F H et al. (2015) PTH and Vitamin D Repress DMP1 in Cementoblasts. J Dent Res 94:1408-16
Chang, Jia; Koh, Amy J; Roca, Hernan et al. (2015) Juxtacrine interaction of macrophages and bone marrow stromal cells induce interleukin-6 signals and promote cell migration. Bone Res 3:15014
Sinder, Benjamin P; Pettit, Allison R; McCauley, Laurie K (2015) Macrophages: Their Emerging Roles in Bone. J Bone Miner Res 30:2140-9
McCauley, Laurie K; Dalli, Jesmond; Koh, Amy J et al. (2014) Cutting edge: Parathyroid hormone facilitates macrophage efferocytosis in bone marrow via proresolving mediators resolvin D1 and resolvin D2. J Immunol 193:26-9

Showing the most recent 10 out of 53 publications